ELATIVE
Live / Registered — Registered (as of 29 Mar 2022)
What this means for you
Registered since 29 Mar 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79312182
- Registration number
- 6681657
- Mark type
- Stylized text
- Filed
- 20 Jan 2021
- Published for opposition
- 11 Jan 2022
- Registered
- 29 Mar 2022
- Attorney of record
- Brooks R. Bruneau
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use
- Class 042 — Scientific and technological services: Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services
Owner
Prosecution history
- 19 Jun 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 12 Sept 2022 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 23 Aug 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 23 Aug 2022 — FINAL DISPOSITION PROCESSED
- 29 Jun 2022 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 08 May 2022 — NEW REPRESENTATIVE AT IB RECEIVED
- 29 Mar 2022 — REGISTERED-PRINCIPAL REGISTER
- 11 Jan 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Jan 2022 — PUBLISHED FOR OPPOSITION
- 10 Jan 2022 — NOTIFICATION PROCESSED BY IB
- 22 Dec 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 22 Dec 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 22 Dec 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Dec 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 09 Dec 2021 — ASSIGNED TO LIE